We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) ...

Michele Johnson, partner with Latham & Watkins, is among the recipients of the The Recorder's 2025 Women Leaders in Tech Law, ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

Analysts' ratings for Sarepta Therapeutics SRPT over the last quarter vary from bullish to bearish, as provided by 30 analysts. In the table below, you'll find a summary of their recent ratings ...

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics SRPT, and it's important for retail traders to take note. \This activity came to our attention today through ...